# To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

> **NCT02542605** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 35 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Placebo
- **DRUG:** PACAP-38 Challenge Agent

## Key facts

- **NCT ID:** NCT02542605
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-11
- **Primary completion:** 2017-09-28
- **Final completion:** 2017-11-08
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02542605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02542605, "To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02542605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*